Vanda Pharmaceuticals | VNDA - Selling And Administration Expenses


Vanda Pharmaceuticals reported $39.28M in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.63M 4.88M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Halozyme Therapeutics USD 57M 10.71M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 247.47M 208K Jun/2026
J&J USD 6.42B 381M Jun/2026
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Ligand Pharmaceuticals USD 29.12M 8.29M Jun/2026
Merck USD 2.89B 219M Jun/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 216M 43M Jun/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 3.41B 496M Jun/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.63B 307M Jun/2026
Takeda JPY 286.51B 5.48B Jun/2026
Teva Pharmaceutical Industries USD 1.03B 34M Jun/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Veracyte USD 55.71M 4.87M Jun/2026